Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Patent disclosure · 2006
- What the patent describes
- Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
- Reported evidence
- Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.
Reported patent results
Reported findings
The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
Population or model Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MS illustrative case | Reported clinical/MRI remission, improved strength, coordination, memory, mood and sleep | One 47-year-old patient also receiving piracetam, pentoxifylline and vitamins · After approximately 3 weeks |
| Chronic-fatigue illustrative case | Reported improvement in general condition, tremor, headaches, coordination and perceived weakness | One 29-year-old patient receiving several other medicines · After a 15-day course |
| Animal maze experiment | 216.6 ± 12.1 s with Bemitil versus 304.9 ± 33.3 s after injury alone; uninjured control 224.3 ± 14 s | 25 mice per group; duration to exploration criterion, not a patient disability score |
No aggregate MS relapse, disability-progression or MRI-lesion outcome is supplied for the 10-patient group. Selected adjunctive cases cannot establish disease modification or ME/CFS efficacy.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Use. Bemitil in multiple sclerosis, with a small historical case series and concurrent treatment; not a controlled MS efficacy trial.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2267319C2 ↗ · 2006-01-10
- Earliest priority / filing
- 2003-07-15 / 2003-07-15
- Original applicant / assignee
- Общество с ограниченной ответственностью "Интер-Кэр"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 35208242 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
Inventors: Олег Валентинович Дорожко (RU); Олег Валентинович Дорожко; Георгий Иванович Ковалев (RU); Георгий Иванович Ковалев; Рамиз Меджидович Салимов (RU); Рамиз Меджидович Салимов.
Study limitations and source details
Study limitations
- Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
- The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
- Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.
Source details
Patent full text
The summary reflects the results reported in the cited source.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
O. V. Dorozhko, G. I. Kovalev, R. M. Salimov. Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006
Related compounds
Bemitil
A synthetic benzimidazole derivative also called bemethyl or Metaprot. Soviet and Russian researchers studied it as an actoprotector, a drug intended to preserve physical work capacity under stress.
Piracetam
A synthetic compound in the racetam family, also known by the brand Nootropil. It appears in neurological research and historical fatigue-related combination studies.